Pradefovir, a liver-targeted prodrug of adefovir against HBV infection.
Article Details
- CitationCopy to clipboard
Tillmann HL
Pradefovir, a liver-targeted prodrug of adefovir against HBV infection.
Curr Opin Investig Drugs. 2007 Aug;8(8):682-90.
- PubMed ID
- 17668370 [ View in PubMed]
- Abstract
Metabasis Therapeutics Inc (previously Ribapharm Inc) is developing pradefovir, an oral liver-targeting prodrug of adefovir developed using its HepDirect technology, for the potential treatment of HBV infection. Phase II clinical trials of pradefovir have been completed.
DrugBank Data that Cites this Article
- Drugs